Cilox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cilox

Property Description
Active ingredient Ofloxacin
Form Ophthalmic solution, otic solution
Pharmacological class Fluoroquinolone antibiotic
Common use Resolution of localized bacterial infections
Origin Synthetic (manufactured)

The medication known by the trade name Cilox is fundamentally defined by its active ingredient, Ofloxacin, a purely synthetic compound. Ofloxacin is a racemate comprising levofloxacin and dextrofloxacin, distinguished by a unique fluorinated carboxyquinolone structure. It is classified as a fluoroquinolone antibiotic, a specialized antimicrobial agent used to combat microbial pathogens. Cilox is primarily recognized by medical professionals for its specific ophthalmic solution and otic solution presentations, a key differentiating feature from other Ofloxacin forms.

Ofloxacin Composition and Topical Solution Form

Cilox contains the active ingredient Ofloxacin as a single-ingredient product, typically prepared as a sterile aqueous solution. This medicine is specifically formulated for topical administration as either an ophthalmic solution (eye drops) or an otic solution (ear drops). For instance, the ophthalmic preparation contains Ofloxacin in a sterile solution at a concentration of 0.3%. Ofloxacin is an effective topical agent in treating superficial infections of the eye and ear. The drug is structurally effective for localized anti-infective treatment. This design for localized application minimizes systemic exposure, ensuring the antibacterial compound achieves high therapeutic concentrations precisely at the affected site, such as the cornea or the ear canal.

Function as a Broad-Spectrum Bactericidal Agent

The general therapeutic purpose of Ofloxacin is to resolve localized bacterial infections by eliminating the responsible microbial organisms. The drug is categorized as a broad-spectrum agent because it is active against a wide range of both Gram-positive and Gram-negative bacteria. Ofloxacin achieves this through a powerful bactericidal action, meaning it directly kills the targeted bacteria. This mechanism involves the inhibition of bacterial DNA replication by blocking the critical bacterial enzymes, DNA gyrase and topoisomerase IV, thereby ensuring the decisive clearance of the infection source. The drug’s primary action is to stop bacterial reproduction, leading to the resolution of the infection. This topical formulation is a clinically recognized choice for managing localized infections where systemic therapy is not indicated.

Regulatory References

  1. NIH StatPearls on Ofloxacin
  2. NIH StatPearls on Ofloxacin - Mechanism of Action

What side effects are possible with Cilox?

Cilox (Ofloxacin topical) is associated with a safety profile primarily defined by local adverse reactions at the site of application, as documented in official regulatory sources. These effects are formally categorized by frequency and the body system affected.

Adverse Reactions Classified by System and Frequency

The most frequent adverse reactions for the ophthalmic solution are classified as Common (affecting 1 to 10 users in 100) and involve Eye disorders, specifically ocular discomfort characterized by burning or stinging, alongside eye irritation and ocular pruritus (itching). Less frequent effects, classified as Uncommon (affecting 1 to 10 users in 1,000), include keratitis (corneal inflammation) and ocular dryness. For the otic solution, common effects include Ear and Labyrinth disorders such as ear pruritus and earache.

Serious Safety Considerations

As a member of the fluoroquinolone class, the medicine is associated with a class-wide warning for serious hypersensitivity reactions, including anaphylaxis and severe dermatological events like Stevens-Johnson Syndrome (SJS). Regulatory guidance mandates that the product must be discontinued at the first sign of a skin rash or any other indicator of a hypersensitivity reaction. Furthermore, prolonged use of the topical solution may lead to the overgrowth of non-susceptible organisms, including fungi, a general safety constraint noted in the prescribing information.

Population-Specific Safety Note

Safety and effectiveness of the ophthalmic solution have not been established in pediatric patients under the age of one year. The official safety documents structure the understanding of risk around its local effects, while maintaining a clear constraint for the entire drug class regarding rare, but severe, systemic reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Cilox (ciprofloxacin ophthalmic/otic) emphasizes the low risk of systemic toxicity in the event of an overdose due to the drug's formulation and minimal absorption into the bloodstream.

Documented Overdose Risk

Government health authorities consistently state that no toxic effects are expected from a topical overdose of the solution or ointment. Similarly, the accidental ingestion of the contents of one single container is also assessed as being unlikely to cause toxic effects.

Required Emergency Actions

The following guidance is based strictly on instructions found within official drug labeling:

  • Topical Overdose: Should a topical overdose occur, the affected eye(s) may be flushed with lukewarm tap water to remove excess product.

  • Accidental Ingestion: If the product is accidentally swallowed, users are instructed to seek emergency medical attention or contact a Poison Help line. Treatment should be symptomatic and supportive in nature.

When to Seek Immediate Medical Help: Immediate medical help is required in the event of accidental ingestion of the product to ensure proper symptomatic management and observation, even though severe toxic effects are not anticipated.

Therapeutic Uses of Cilox

What Cilox Treats: Main Uses and Benefits

Cilox (Ciprofloxacin ophthalmic) is a topical medication generally used to provide short-term symptomatic assistance and supportive relief for certain infections of the eye. Its use is considered relevant across therapeutic domains where increased discomfort or functional stability is temporarily affected by infection.

The medication is applied in clinical settings when supportive symptom management is appropriate. It plays a role in managing conditions presenting with acute episodes, including conjunctivitis and corneal ulcers.

“The medication is commonly used when short-term symptomatic assistance is needed to address symptoms that interfere with daily comfort.”

It helps address symptom clusters that may become disruptive, such as inflammation, redness, ocular discharge, or severe pain. This provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during difficult episodes.

Quick Fact: Relief for Ocular Discomfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Cilox?

Official regulatory documents define specific populations who must not use Cilox (ciprofloxacin ophthalmic) and others for whom its use is restricted.


Contraindicated Populations (Must Not Use)

Contraindication
Hypersensitivity: Individuals with a known allergic reaction or hypersensitivity to ciprofloxacin or to any other component contained in the medication.
Quinolone Sensitivity: Individuals with a known hypersensitivity to any other quinolone class antibiotic.

Restricted or Special Consideration Populations

Population Eligibility Status
Pediatric Patients (Ointment) Safety and effectiveness of the ophthalmic ointment formulation have not been established in patients below the age of two years.
Pregnancy Use is classified as Pregnancy Category C (older FDA classification) or generally advised only if the potential benefit justifies the potential risk.
Nursing Mothers Caution is advised, as it is not known whether topically applied ciprofloxacin is excreted in human milk, though oral forms are known to be.

These official statements structure the eligibility profile, creating clear exclusions based on drug-specific and drug-class allergies, and imposing specific age constraints for the ointment formulation. All other uses require the prescriber to weigh benefit against risk, especially in the context of pregnancy and lactation, as advised by governmental guidance.

What should I know about interactions with other medicines?

Cilox contains the active ingredient Ofloxacin, a fluoroquinolone antibiotic. While the topical solution results in minimal systemic absorption, the official interaction profile for Ofloxacin addresses potential interactions based on the systemic use of the drug.

Official Interaction Restrictions

Classification Interacting Agents (Examples) Official Description/Requirement
Formal Contraindication Pimozide, Thioridazine, Dronedarone, Cisapride Prohibited combination due to documented risk of additive QTc prolongation.
Absorption Interference Mineral Antacids (Al/Mg), Sucralfate, Iron/Zinc Supplements Mandatory timing separation is required; administration must be separated by at least 2 hours to avoid significantly reduced Ofloxacin exposure.
Pharmacodynamic Risk Warfarin and its derivatives Co-administration may enhance the anticoagulant effect, requiring careful monitoring of coagulation tests (PT/INR).
Reduced Clearance Probenecid, Cimetidine, Furosemide Substances documented to interfere with renal tubular secretion, which may result in increased systemic exposure of Ofloxacin.

Pharmacodynamic interactions with agents like Theophylline or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are documented due to the potential to lower the seizure threshold. High intake of dietary Calcium may also reduce Ofloxacin absorption. The primary focus of the regulatory profile is to manage the risk of reduced exposure and the potential for additive toxicities when systemic absorption occurs.

Mechanism of Action

Cilox contains Ciprofloxacin, an agent that exerts its effect by targeting essential processes within the bacterial cell's core genetic machinery. The drug's highly specific mechanism leads to the irreversible death of susceptible bacteria, which establishes the agent's characteristic physiological effect.

The primary mechanism involves inhibition of two vital bacterial enzymes, DNA Gyrase and Topoisomerase IV, which are necessary for managing the bacterial DNA structure, replication, and separation during cell division. This action engages the mechanistic domain of nucleic acid metabolism modulation, halting the fundamental ability of the cell to function and reproduce. The drug locks these target enzymes onto the bacterial DNA, creating an overwhelming number of double-strand DNA breaks that cannot be repaired. This acute genetic damage initiates a lethal cascade, resulting in the bactericidal physiological effect. This action results in the cessation of bacterial proliferation within the local environment. The effectiveness can be constrained by bacterial defense mechanisms, primarily efflux pump proteins that actively transport the drug out of the cell, reducing the effective intracellular concentration.

Dosage and Administration Information

Administration of Cilox

Cilox is a topical antibiotic medication available in various formulations, typically as eye drops or ear drops. The method of application depends on the specific condition being treated and the anatomical site involved.

General Preparation

Before using the medication, it is important to ensure that the hands are thoroughly cleaned. Proper hygiene helps prevent the introduction of additional bacteria or contaminants to the affected area. The container should be handled carefully to avoid contact between the dropper tip and any surface, including the eye, ear, or skin.

Application Techniques

Ophthalmic Use

For ophthalmic applications, the medication is delivered into the conjunctival sac. This is generally achieved by tilting the head back and gently pulling the lower eyelid down to create a small pocket. The prescribed amount of solution is then placed into this pocket. Following application, the eye should be closed gently. Applying light pressure to the inner corner of the eye (the nasolacrimal duct) for a short period can help keep the medication in contact with the ocular surface.

Otic Use

For otic applications, the individual should lie down with the affected ear facing upward. The solution is then instilled into the ear canal. To facilitate the flow of the medication, the earlobe may be gently manipulated. Remaining in this position for a few minutes allows the drops to penetrate the ear canal effectively.

Consistency and Storage

To maintain effective levels of the medication at the site of infection, the applications are typically spaced at regular intervals throughout the day. It is standard practice to continue the application for the full duration specified by a healthcare professional, even if symptoms appear to improve before the course is finished.

The container should be kept tightly closed when not in use and stored according to the temperature requirements indicated on the product packaging. If the solution becomes cloudy or changes color, it should no longer be used.

Recent Clinical Evidence

Evidence for Use in Bacterial Corneal Ulcers

The research for Ciprofloxacin ophthalmic solution in this severe condition primarily stems from Randomized Controlled Trials (RCTs). These studies evaluated patient groups, including adults and pediatric patients 1 year of age, focusing on outcomes related to microbial eradication and the measured re-epithelialization of the corneal surface. An observed pattern described in the data was the presence of a temporary white crystalline deposit formed in some patients; this clinical factor was monitored to track its resolution. The research primarily focuses on the acute treatment phase, and long-term effects are not fully established.

Evidence for Use in Bacterial Conjunctivitis

Evidence for this superficial infection is largely derived from short-term RCTs that research examined symptom changes and were often evaluated in comparison with other anti-infective agents. These studies explored outcomes linked to inflammatory states, measuring the resolution of signs such as redness and discharge, alongside microbial clearance. As follow-up durations were limited to the acute phase, research provides limited information for long-term outcomes.

Evidence Landscape for Otic Infections

The research base for localized bacterial infections of the ear canal (Acute Otitis Externa) was evaluated in RCTs that monitored outcomes such as physical discomfort (ear pain) and changes in discharge. The data show patterns related to the measured rates of pre-defined clinical endpoints. However, much subsequent research focused on combination drug products containing Ciprofloxacin and a corticosteroid. The direct data for the single-ingredient otic solution is therefore more limited.

Long-Term Studies, Special Populations, and Uncertainty

Across all indications, follow-up durations were limited, with research primarily focusing on the acute treatment course. While pediatric patients 1 year of age were included in trials, and specific studies included neonates for conjunctivitis, data for certain subgroups remain insufficient. The evidence is limited regarding the long-term durability of the anti-infective effect. Furthermore, evidence quality varies across studies, and continuous tracking of local pathogen susceptibility is required.

Key Studies & References Ciprofloxacin (StatPearls)

Frequently Asked Questions (FAQ)

Common questions about Cilox (FAQ)

Q: What is the difference between Cilox and other similar eye drops?

Cilox’s active ingredient, Ofloxacin, is classified as a fluoroquinolone antibiotic. This class of medicine is specifically indicated by official sources for treating bacterial infections of the eye or ear. The drug’s specific properties align with treatment for certain bacterial pathogens, as documented in official information.

Q: Are there any long-term side effects reported with Cilox use?

According to official regulatory information, safety and effectiveness data are primarily focused on the acute treatment course, which is the period during which the medicine is actively used. Regulatory evidence for topical Ofloxacin does not currently establish comprehensive information regarding long-term effects.

Q: Are there any specific activities to avoid while using Cilox?

Official warnings indicate that the medicine may cause temporary blurred vision and may impair thinking or reactions. Official warnings state that patients must avoid driving or operating machinery or doing anything that requires clear vision until the effect subsides.

Q: What is the maximum number of days Cilox is typically used?

The duration of use is entirely condition-dependent. The length of use is based on the specific condition being treated, as documented in the official dosage information. For example, official product information describes typical courses of 7 days for bacterial conjunctivitis, or up to 7 to 9 days for a corneal ulcer.

Q: Can people with kidney problems use Cilox?

Topical use of Cilox results in minimal absorption into the body, but oral medicines from the same drug class (fluoroquinolones) are used with caution in individuals with a history of kidney disease. The appropriateness of use is a matter for individual medical judgment.

Q: Does Cilox work on viral eye infections?

No. Official product information states that Cilox is a quinolone antibiotic indicated only for treating bacterial infections. This medicine will not treat infections caused by viruses or fungi.

Q: Are there different strengths or concentrations of Cilox?

Official regulatory documentation indicates that the ophthalmic solution (eye drops) is formulated as a single strength. This concentration contains 0.3% ofloxacin.

Q: Can Cilox interact with eye vitamins or supplements?

While interaction risk is low with topical use, regulatory documents for oral Ofloxacin state that a timing separation is required from supplements containing minerals like iron, zinc, or calcium. This separation is necessary to prevent the potential reduction of Ofloxacin absorption.

Q: Why is it important to use Cilox for the full prescribed time?

Official product information notes that using the medicine for the full treatment time is important even if symptoms improve quickly. Discontinuing treatment prematurely may result in the infection not being fully resolved and may contribute to the development of antibiotic resistance.

Q: Does the time of day matter when using Cilox?

The dosing schedule can be very specific, which means timing is important. For intensive treatments like a corneal ulcer, the official schedule may require instillation every 30 minutes while awake. This schedule indicates that adherence to the precise timing and frequency described is necessary to align with the clinical trial parameters for efficacy.

Q: How quickly do people usually start to feel better after using Cilox?

Regulatory guidance advises patients to contact their healthcare team if symptoms do not improve within 2 to 3 days of starting treatment. This provides a timeframe mentioned in regulatory guidance for when a lack of improvement should prompt a clinical review.

Q: Does Cilox require a prescription?

Yes, the active ingredient in Cilox, Ofloxacin ophthalmic solution, is generally classified as a medicine that is only available with a valid prescription.

Q: If I miss a dose of Cilox, what is the generally accepted advice?

Official product information generally describes using the medicine as soon as possible if a dose is missed, unless it is nearly time for the next scheduled dose. If so, official product information generally describes skipping the missed dose and returning to the regular schedule. Extra medicine should not be used to make up a missed dose.

Q: Does Cilox cause blurry vision right after application?

Yes, official adverse reaction data lists temporary blurred vision as a common side effect that may occur immediately following the application of the eye drops. The effect should be temporary.

Q: What happens if Cilox is used past its expiration date?

Official labeling requires the solution to be discarded 28 days (or 4 weeks) after first opening the bottle, even if there is medicine remaining. Unused or expired medication must always be disposed of using proper methods.

Q: How can I tell if a bottle of Cilox is contaminated?

Official instructions caution patients not to use the eye drops if they observe that the liquid has changed color or if there are particles or cloudiness visible in the solution. Using a contaminated product is a known safety risk, which is why product quality should be verified before use.

Q: Is Cilox known to cause sensitivity to sunlight?

Yes, official adverse effect data lists increased sensitivity of the eye to light (photophobia) as a reported side effect of the medicine. This effect suggests that eye protection from light may be helpful.

Q: Does using Cilox make it harder to drive or operate machinery?

Official warnings note that the medicine may cause temporary effects like blurred vision or other impairments. Official warnings state that patients must avoid driving, using machinery, or engaging in activities that require clear vision until they can be performed safely.

Q: What is the procedure if someone accidentally swallows Cilox?

Official information indicates that an overdose of ophthalmic Ofloxacin is not typically expected to be dangerous due to the small amount of drug involved. If anyone accidentally swallows the medicine, safety literature advises contacting a poison control center or seeking emergency medical attention.

Q: Can I use other eye drops at the same time as Cilox?

Official guidance advises against using other eye drops or medications during treatment with Ofloxacin unless specifically directed by a doctor. If multiple topical agents are prescribed, a minimum of 10 minutes should pass between instillations.

Q: Is Cilox used in veterinary medicine?

Yes, official regulatory resources note that Ofloxacin ophthalmic is a medicine that is sometimes used in veterinary medicine for the treatment of certain animal eye infections.

Q: Does Cilox contain preservatives?

Yes, official product descriptions indicate that the solution typically contains a preservative to maintain sterility, often an agent such as benzalkonium chloride.

Q: Can older adults use Cilox without specific concerns?

Official regulatory documents state there is no specific information comparing the use of ophthalmic Ofloxacin in the elderly compared to younger adults. No different side effects or problems are explicitly expected in older adults than those seen in younger age groups.

How should Cilox be stored and disposed of?

Storage and Disposal of Cilox (Ciprofloxacin Ophthalmic Solution)

Official labeling defines strict conditions for storing and disposing of Cilox to ensure its stability and sterility.


Storage Requirements

Condition Requirement
Temperature Store at 25 C (77 F), with excursions permitted up to 30 C
Prohibited Do not refrigerate or freeze the solution.
Protection Keep the product out of the reach and sight of children. Protect from light.
Container Keep the bottle tightly closed when not in use. Do not touch the dropper tip to any surface.
Stability The solution must be discarded 28 days after first opening.

Disposal Protocol

Unused or expired Cilox must not be disposed of via wastewater or household waste. Consult a pharmacist for proper disposal methods regarding pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cilox found in:

A-Z Index: